The latest FDA warning-letter table, current as of June 16, 2026, listed multiple CDER letters in the same telehealth claims lane: Maximus Health, Trinity HealthCare Supply dba altRx, Glow Medispa dba Mint Med, Ezra Holdco dba Ezra, and Public Health Solution dba DrMedHealth.
For teams watching FDA enforcement, the point is not that every telehealth page has the same issue. The point is that the agency can review public websites and patient-facing marketing as part of a claims analysis.
The pattern
The letters sit in the same category on FDA's table: false and misleading claims or misbranding tied to telehealth. That makes the batch useful as a monitoring signal even before a company reads each letter in full.
When several letters land together, a compliance team can use the cluster as a prompt to look at its own public surfaces: landing pages, condition pages, comparison language, prescribing funnels, FAQ copy, testimonials, and calls to action.
What to check first
- Do public pages describe benefits in a way that outruns approved labeling or evidence?
- Are risk, limitation, and prescribing-context statements visible near stronger claims?
- Do funnels, quizzes, or intake pages imply a treatment outcome before clinician review?
- Are affiliates, paid pages, and old campaign URLs still live?
- Can the team show who owns review of web copy after launch?
Why FDA Warning Monitor tracks clusters
One letter may be a company-specific event. A cluster can point to a repeatable review theme. That is why FDA Warning Monitor watches dates, categories, offices, subjects, and repeated issue types instead of treating every source link as an isolated headline.
Sources
FDA Warning Letters table, current as of June 16, 2026
FDA warning letter, Maximus Health, Inc. dba Maximus, June 8, 2026